UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): November 20, 2003
AMERICAN VANGUARD CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware |
0-6354 |
95-2588080 | ||
| (State or other jurisdiction | Commission File Number | (I.R.S. Employer | ||
| of incorporation) | Identification No.) |
4695 MacArthur Court
Newport Beach, California 92660
(Address of principal executive offices)
Registrant’s telephone number: (949) 260-1200
| Item | 5. Other Events. |
On November 20, 2003, American Vanguard Corporation issued the press release attached hereto as Exhibit 99.4. The release announced that Amvac Chemical Corporation, a wholly-owned subsidiary of American Vanguard Corporation, has signed a definitive agreement to acquire certain assets related to the active ingredient dichlorvos ( “DDVP” ) used in the animal health business and marketed primarily under the trade name Nuvan® from Novaritas Animal Health, Inc., all as more particularly described in Exhibit 99.4.
Item 7. Exhibits.
| 99.4 | Press release issued November 20, 2003. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERICAN VANGUARD CORPORATION (Registrant) | ||
| By: | /s/ JAMES A. BARRY | |
| James A. Barry Senior Vice President Chief Financial Officer | ||
| Date: November | 24, 2003 |
3
INDEX TO EXHIBITS
| Exhibit No. |
Description | |
| 99.4 |
Press release |
4